Stevanato Group resumed with an Overweight at Stephens

Stephens resumed coverage of Stevanato Group (STVN) with an Overweight rating and $27 price target view Stevanato is a leading glass containment solution provider that is “uniquely positioned to benefit” in the defensive healthcare industry with strong tailwinds, including the growing demand for biologics, injectable medications, GLP-1s, and stricter regulations that are expected to drive high-single digit to low-double-digit long-term revenue growth, the analyst tells investors. Headwinds such as destocking, engineering challenges, and facility startup inefficiencies are reaching a turning point, creating significant opportunities for revenue growth and margin expansion, the analyst added.